OR 462

Known as: OR-462, OR462 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-1998
02419881998

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
The efficacy of levo-DOPA in the treatment of Parkinson's disease is potentiated by blockade of its peripheral metabolism with… (More)
Is this relevant?
1992
1992
Nitecapone [3-(3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione] [OR-462] is a catechol-O-methyltransferase inhibitor with… (More)
Is this relevant?
1992
1992
PET studies were performed to investigate the effects of a new cathechol-O-methyltransferase (COMT) inhibitor, nitecapone (OR-462… (More)
Is this relevant?
1991
1991
We studied the effectiveness of OR-611 and OR-462, two novel inhibitors of the enzyme catechol-O-methyltransferase (COMT), on 3-O… (More)
Is this relevant?
1991
1991
3-Nitropyrocatechols are very potent and selective inhibitors of catechol-O-methyltransferase (COMT). LD50 values of three of… (More)
Is this relevant?
1990
1990
3-O-Methyldopa (OMD) is the principal circulating metabolite formed from exogenously administered levodopa. We studied the effect… (More)
Is this relevant?
1989
1989
The inhibition kinetics of rat liver and duodenum soluble catechol-O-methyltransferase (COMT) with a disubstituted catechol OR… (More)
Is this relevant?
1988
1988
A selective catechol-O-methyltransferase inhibitor, OR-462, was studied for its ability to affect pharmacokinetic properties of L… (More)
Is this relevant?
1988
1988
Catechol-O-methyltransferase (COMT) has an important role in the extraneuronal inactivation of catecholamine neurotransmitters… (More)
Is this relevant?
1988
1988
Novel bisubstituted catechols were found to be potent and highly selective COMT inhibitors in vitro. One of them, OR-462 (3-(3,4… (More)
Is this relevant?